Effects of zonisamide monotherapy in children with epilepsy

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Epilepsy is a common neurological disorder in children.
• Effective antiepileptic drugs are crucial for managing pediatric epilepsy.
• Zonisamide is an established antiepileptic drug with a broad spectrum of action.

Purpose of the Study:

• To evaluate the efficacy and safety of zonisamide as monotherapy in pediatric patients with epilepsy.
• To determine seizure control rates and identify adverse events associated with zonisamide treatment in children.

Main Methods:

• A cohort of 77 pediatric patients (8 months-15 years) with epilepsy received zonisamide monotherapy.
• Dosages were initiated at approximately 2 mg/kg/day and titrated up to 12 mg/kg/day.
• Efficacy and safety data were collected, with early withdrawals due to side effects included in safety analyses.

Main Results:

• High seizure freedom rates were observed across different epilepsy types: 82% in cryptogenic/symptomatic partial epilepsy, 91% in cryptogenic/symptomatic generalized epilepsy, 100% in idiopathic partial epilepsy, and 89% in idiopathic generalized epilepsy.
• Overall, 39% of patients reported side effects, most commonly somnolence (11.7%), decreased spontaneity (7.8%), anorexia (6.5%), and rash (6.5%).
• Nine patients (11.7%) were withdrawn due to adverse events.

Conclusions:

• Zonisamide monotherapy demonstrates significant efficacy in controlling seizures in pediatric patients with various epilepsy syndromes.
• It is a potential broad-spectrum antiepilepsy agent for children.
• The safety profile is generally acceptable, with manageable side effects.